1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,560 | 0,590 | 16:31 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.05. | RECBIO-B (02179): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON MAY 28, 2026 | - | HKEx | ||
| JIANGSU RECBIO TECHNOLOGY Aktie jetzt für 0€ handeln | |||||
| 30.04. | RECBIO-B (02179): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 30.04. | RECBIO-B (02179): INSIDE INFORMATION ANNOUNCEMENT COMPLETION OF FULL CIRCULATION OF H SHARES | 3 | HKEx | ||
| 29.04. | RECBIO-B (02179): FORM OF PROXY FOR USE AT THE 2025 ANNUAL GENERAL MEETING TO BE HELD ON THURSDAY, MAY 28, 2026 | - | HKEx | ||
| 29.04. | RECBIO-B (02179): NOTICE OF 2025 ANNUAL GENERAL MEETING | - | HKEx | ||
| 29.04. | RECBIO-B (02179): CIRCULAR OF 2025 ANNUAL GENERAL MEETING | - | HKEx | ||
| 29.04. | RECBIO-B (02179): 2025 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | - | HKEx | ||
| 29.04. | RECBIO-B (02179): 2025 ANNUAL REPORT | 1 | HKEx | ||
| 24.03. | RECBIO-B (02179): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025 AND PROPOSED CHANGE OF THE USE OF PROCEEDS | 1 | HKEx | ||
| 24.03. | RECBIO-B (02179): CHANGE OF JOINT COMPANY SECRETARIES, AUTHORISED REPRESENTATIVE AND PROCESS AGENT | 1 | HKEx | ||
| 12.03. | RECBIO-B (02179): DATE OF BOARD MEETING | - | HKEx | ||
| 06.02. | RECBIO-B (02179): INSIDE INFORMATION ANNOUNCEMENT GRANT OF LISTING APPROVAL BY THE STOCK EXCHANGE FOR THE H SHARE FULL CIRCULATION PLAN OF THE COMPANY | 1 | HKEx | ||
| 30.01. | RECBIO-B (02179): INSIDE INFORMATION ANNOUNCEMENT ISSUANCE OF FILING NOTICE BY THE CSRC FOR THE H SHARE FULL CIRCULATION PLAN OF THE COMPANY | 1 | HKEx |
13 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| DYNE THERAPEUTICS | 22,675 | -4,85 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD) | - Priority Review granted; PDUFA target action date set for January 21, 2027 - - Submission for Accelerated Approval based on dystrophin as a surrogate endpoint - - In the registrational expansion... ► Artikel lesen | |
| QIAGEN | 35,825 | +1,32 % | AKTIEN IM FOKUS 2: Danaher enttäuscht Anleger - Auch Sartorius-Kurs leidet | (neu: Kurse mit Danaher im offiziellen Handel, Analystenstimmen) FRANKFURT/NEW YORK (dpa-AFX) - Der Quartalsbericht von Danaher hat im Diagnostikbereich am Dienstag international eine Welle der Enttäuschung... ► Artikel lesen | |
| LAKEWOOD-AMEDEX BIOTHERAPEUTICS | 4,310 | +131,72 % | Lakewood-Amedex Biotherapeutics Inc.: Lakewood-Amedex Biotherapeutics Announces Preclinical Safety Data Supporting Clinical Dose Selection for Upcoming Phase 2a Trial of Nu-3 Gel | Nu-3 is a gel formulation of a Bisphosphocin® compound targeting the topical treatment of infected diabetic foot ulcers with low likelihood of producing systemic... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 134,25 | +0,04 % | Apogee Therapeutics Aktie erreicht Rekordhoch von 134,34 USD | ||
| SUMMIT THERAPEUTICS | 15,120 | +3,35 % | Summit Therapeutics Inc. - 8-K, Current Report | ||
| ERASCA | 19,070 | -1,60 % | Erasca closes $632.5 million public stock offering | ||
| PRAXIS PRECISION MEDICINES | 310,88 | -2,20 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| BIONTECH | 80,95 | -0,37 % | Heftige Ausschläge im LifeScience-Sektor! Bayer, Vidac Pharma, BioNTech, Moderna und Evotec im Brennpunkt | Hier geht's rund! Aktuell erlebt die Krebsforschung durch die Verschmelzung von Zellanalyse und digitaler Präzision eine historische Zeitenwende. Mit einem neuen Management versucht BioNTech seine revolutionäre... ► Artikel lesen | |
| EVOTEC | 3,452 | -2,32 % | Evotec-Aktie nach Zahlen: Kurs rutscht -36% ab | Die Evotec-Aktie geriet nach einer drastischen Prognosesenkung massiv unter Druck und verlor nachbörslich zeitweise rund -36%. Das Hamburger Biotechunternehmen erwartet für 2026 nun deutlich weniger... ► Artikel lesen | |
| TANGO THERAPEUTICS | 28,410 | -2,10 % | How Much Upside is Left in Tango Therapeutics (TNGX)? Wall Street Analysts Think 49.48% | ||
| MODERNA | 51,91 | -0,82 % | Moderna Is Up 109% in 2026. Jim Cramer Just Called It 'Finally Investable Again.' Is the Stock a No-Brainer Buy on Its Recent Pullback? | ||
| BIOGEN | 177,08 | -0,60 % | Biogen Inc.: Biogen Appoints Michael J. Parini as Chief Legal Officer | CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the appointment of Michael J. Parini as Chief Legal Officer, effective August 3, 2026. Parini will serve... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 9,460 | +0,42 % | Vir Biotechnology, Inc.: Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026 | - Oral presentation of complete Week 96 data from the Phase 2 SOLSTICE trial in chronic hepatitis delta selected for inclusion in "Best of EASL 2026" by EASL - Poster presentation of Week 48... ► Artikel lesen | |
| COGENT BIOSCIENCES | 39,300 | -0,86 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| RELAY THERAPEUTICS | 19,200 | -0,52 % | Canaccord initiates Relay Therapeutics stock with buy rating |
JIANGSU RECBIO TECHNOLOGY CO LTD gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,550 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu JIANGSU RECBIO TECHNOLOGY CO LTD finden Sie auf Wallstreet Online.